Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.intimp.2020.106926 http://scihub22266oqcxt.onion/10.1016/j.intimp.2020.106926 32889236!7455148!32889236     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+Immunopharmacol 2020 ; 88 (ä): 106926 Nephropedia Template TP {{tp|p=32889236|t=2020. Outcome of COVID-19 patients with use of Tocilizumab: A single center experience |pdf=|usr=}}{{32889236}} gab.com Text Outcome of COVID-19 patients with use of Tocilizumab: A single center experience JO: Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32889236 #FOAvip COVID-19 pandemic has become a global concern. Cytokine release syndrome (CRS) complicates acute respiratory distress syndrome (ARDS) and causes multi-organ failure which can subsequently lead to mortality in COVID-19 patients. Tocilizumab, an interleukin-6 antagonist, has shown to salvage patients with cytokine release storm. In this study, we aim to evaluate therapeutic response of Tocilizumab in COVID-19 patients. A single-arm retrospective review of 40 patients with COVID-19, admitted to The Aga Khan University Hospital Karachi, from March 2020 to May 2020 was performed. Selection of patients for use of Tocilizumab was based on severity of disease, rapid clinical deterioration, presence of CRS and absence of any absolute contraindication to Tocilizumab. Improvement after Tocilizumab was defined as improvement in oxygen requirement and inflammatory parameters. Serum levels of inflammatory cytokines like C-reactive protein, ferritin, D-dimer and lactate dehydrogenase levels were monitored before and after administering Tocilizumab. Mean age was 62.4 years and 33 (82.5%) were male. 19 (47.5%) patients were critically sick, 18 (45%) were severely sick and 3 (7.5%) were moderately sick. 29 (77.5%) patients showed significant improvement in oxygen requirement, inflammatory parameters and chest x-rays, out of which 28 patients were discharged home. The mean duration between administration of Tocilizumab and overall improvement was 4.3 +/- 3.2 days. Hence, Tocilizumab can be used as a possible treatment option in patients with COVID-19 induced CRS but needs monitoring for its adverse effects. Twit Text FOAVip Outcome of COVID-19 patients with use of Tocilizumab: A single center experience ????Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32889236 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32889236 #FOAvip English Wikipedia <ref>{{Cite pmid|32889236}}</ref> Outcome of COVID-19 patients with use of Tocilizumab: A single center experience #MMPMID32889236 Zain Mushtaq M; Bin Zafar Mahmood S; Jamil B; Aziz A; Ali SA Int Immunopharmacol 2020[Nov]; 88 (ä): 106926 PMID32889236show ga COVID-19 pandemic has become a global concern. Cytokine release syndrome (CRS) complicates acute respiratory distress syndrome (ARDS) and causes multi-organ failure which can subsequently lead to mortality in COVID-19 patients. Tocilizumab, an interleukin-6 antagonist, has shown to salvage patients with cytokine release storm. In this study, we aim to evaluate therapeutic response of Tocilizumab in COVID-19 patients. A single-arm retrospective review of 40 patients with COVID-19, admitted to The Aga Khan University Hospital Karachi, from March 2020 to May 2020 was performed. Selection of patients for use of Tocilizumab was based on severity of disease, rapid clinical deterioration, presence of CRS and absence of any absolute contraindication to Tocilizumab. Improvement after Tocilizumab was defined as improvement in oxygen requirement and inflammatory parameters. Serum levels of inflammatory cytokines like C-reactive protein, ferritin, D-dimer and lactate dehydrogenase levels were monitored before and after administering Tocilizumab. Mean age was 62.4 years and 33 (82.5%) were male. 19 (47.5%) patients were critically sick, 18 (45%) were severely sick and 3 (7.5%) were moderately sick. 29 (77.5%) patients showed significant improvement in oxygen requirement, inflammatory parameters and chest x-rays, out of which 28 patients were discharged home. The mean duration between administration of Tocilizumab and overall improvement was 4.3 +/- 3.2 days. Hence, Tocilizumab can be used as a possible treatment option in patients with COVID-19 induced CRS but needs monitoring for its adverse effects. |Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects/*therapeutic use[MESH] |Betacoronavirus[MESH] |Biomarkers/blood[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/immunology/mortality[MESH] |Critical Care/*methods[MESH] |Critical Illness[MESH] |Female[MESH] |Humans[MESH] |Interleukin-6/blood[MESH] |Male[MESH] |Middle Aged[MESH] |Pakistan[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/immunology/mortality[MESH] |Respiration, Artificial[MESH] |Retrospective Studies[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH]Outcome of COVID-19 patients with use of Tocilizumab: A single center (epmc).pdf DeepDyve Pubget Overpricing